1 / 1

Cobimetinib(Cotellic)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

TABLET

Validity period:

Not specified in the description.

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Cotellic (cobimetinib) is an oral kinase inhibitor primarily utilized in oncology. It works by inhibiting MEK1 and MEK2, key enzymes in the MAPK/ERK signaling pathway, which plays a crucial role in cell division and survival. By blocking this pathway, Cotellic helps slow down the growth of cancer cells.

This drug is approved for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. Additionally, it is approved for the treatment of adult patients with histiocytic neoplasms as a monotherapy. It is essential for clinicians to confirm the presence of the BRAF V600E or V600K mutation before initiating Cotellic in melanoma patients.

Generic name

Cobimetinib(Cotellic)

English name

Cobimetinib

Alternative Names

Cotellic

Drug prices

Indications

Unresectable or Metastatic Melanoma:

For adults with BRAF V600E/K mutation-positive disease, in combination with vemurafenib.

Histiocytic Neoplasms:

As monotherapy for adults with histiocytic neoplasms (e.g., Erdheim-Chester disease, Langerhans cell histiocytosis).

Therapeutic Target

Reversible inhibitor of MEK1/2 (mitogen-activated protein kinase kinase 1/2), blocking the RAS/RAF/MEK/ERK pathway.

Active Ingredients

Cobimetinib fumarate.

Dosage form

TABLET

specifications

Bottles containing 63 tablets (20 mg each).

Description

Physical Properties: White to off-white, round tablets debossed with “COB” on one side.

Inactive Ingredients:

Core: Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate.

Coating: Polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, talc.

Dosage and Administration

Recommended Regimen:

Melanoma:

60 mg once daily for 21 days followed by 7 days off (28-day cycle).

Confirm BRAF V600 mutation before initiation.

Histiocytic Neoplasms:

60 mg once daily for 21 days followed by 7 days off (28-day cycle).

Dose Modifications:

First Reduction: 40 mg once daily.

Second Reduction: 20 mg once daily.

Permanent Discontinuation: If toxicity persists at 20 mg.

Administration Notes:

Take with or without food.

Missed Dose/Vomiting: Skip and resume next scheduled dose.

CATEGORY NAVIGATION